European Journal of Biotechnology and Bioscience


ISSN: 2321-9122

Vol. 3, Issue 9 (2015)

Infliximab: Biological response modifier, chimeric IgG1 therapeutic recombinant monoclonal antibody

Author(s): Harit Kasana
Abstract: Infliximab is a chimeric IgG1κ monoclonal antibody (composed of human constant and murinernvariable regions) specific for human tumor necrosis factor-alpha (TNFα). Infliximab is produced by arnrecombinant cell line cultured by continuous perfusion and is purified by a series of steps that includesrnmeasures to inactivate and remove viruses. The annual global sale of Infliximab was $8 billion in 2013,rnaccording to industry data. This article describes the overview of infliximab including mechanism ofrnaction, indications and development genetics.
Pages: 47-50  |  1312 Views  663 Downloads
library subscription